Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.

Autor: Takeshima M; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan., Yoshizawa K; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan., Ogasawara M; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan., Kudo M; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan., Itoh Y; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan., Ayabe N; Department of Regional Studies and Humanities, Faculty of Education and Human Studies, Akita University, Akita, Japan., Mishima K; Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.

Publikováno v: JAMA network open [JAMA Netw Open] 2024 Apr 01; Vol. 7 (4), pp. e246865. Date of Electronic Publication: 2024 Apr 01.

Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.

Autor: Liang L; Department of Psychiatry, Renmin Hospital of Wuhan University, Hubei Zhang Road (formerly Ziyang Road), Wuchang District No. 99, Jiefang Road 238, Wuhan, Hubei province, China., Huang Y; Department of Pathology, Renmin Hospital of Wuhan University, Hubei Zhang Road (formerly Ziyang Road), Wuchang District No. 99, Jiefang Road 238, Wuhan, Hubei province, China., Xu R; Department of Medical Oncology, People's Hospital of Xinjiang Uygur, Urumqi, China., Wei Y; Department of Psychiatry, Renmin Hospital of Wuhan University, Hubei Zhang Road (formerly Ziyang Road), Wuchang District No. 99, Jiefang Road 238, Wuhan, Hubei province, China., Xiao L; Department of Psychiatry, Renmin Hospital of Wuhan University, Hubei Zhang Road (formerly Ziyang Road), Wuchang District No. 99, Jiefang Road 238, Wuhan, Hubei province, China., Wang G; Department of Psychiatry, Renmin Hospital of Wuhan University, Hubei Zhang Road (formerly Ziyang Road), Wuchang District No. 99, Jiefang Road 238, Wuhan, Hubei province, China. Electronic address: wgh6402@163.com.

Publikováno v: Sleep medicine [Sleep Med] 2019 Oct; Vol. 62, pp. 6-13. Date of Electronic Publication: 2019 Apr 06.

Evaluation of anticholinergic burden in elderly outpatients and the risk factors.

Autor: Lu X; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008. luxikuis@163.com.; Department of Pharmacology, School of Pharmacy, Dali University, Dali Yunnan 671000. luxikuis@163.com.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China. luxikuis@163.com., Huang H; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008. huanghangxing97@163.com.; Department of Pharmacology, School of Pharmacy, Dali University, Dali Yunnan 671000. huanghangxing97@163.com.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China. huanghangxing97@163.com., Huang Y; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China., Zhang L; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China., Wu X; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008.; Department of Pharmacology, School of Pharmacy, Dali University, Dali Yunnan 671000.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China., Wang Z; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008.; Department of Pharmacology, School of Pharmacy, Dali University, Dali Yunnan 671000.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China., Xiao J; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008. admanoas@163.com.; National Clinical Research Center for Geriatric Disorders; Institute for Rational and Safe Medication Practices, Xiangya Hospital, Central South University, Changsha 410008, China. admanoas@163.com.

Publikováno v: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences [Zhong Nan Da Xue Xue Bao Yi Xue Ban] 2023 Jan 28; Vol. 48 (1), pp. 114-122.

Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey.

Autor: Kesselheim AS; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Sinha MS; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Rausch P; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Lu Z; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Tessema FA; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Lappin BM; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Zhou EH; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Dal Pan GJ; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Zwanziger L; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Ramanadham A; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Loughlin A; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Enger C; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Avorn J; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO., Campbell EG; Aaron S. Kesselheim, M.D., J.D., M.P.H., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Michael S. Sinha, M.D., J.D., M.P.H. is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Paula Rausch, Ph.D., R.N., is with the U.S. Food and Drug Administration in Silver Spring, MD; Zhigang Lu, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Frazer A. Tessema, B.A., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Brian M. Lappin, M.A., is with the U.S. Food and Drug Administration in Silver Spring, MD; Esther H. Zhou, M.D., Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Gerald J. Dal Pan, M.D., M.H.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Lee Zwanziger, Ph.D., is with the U.S. Food and Drug Administration in Silver Spring, MD; Amy Ramanadham, Pharm.D., M.S., is with the U.S. Food and Drug Administration in Silver Spring, MD; Anita Loughlin, Ph.D., is with Optum in Boston, MA; Cheryl Enger, Ph.D., is with Optum in Boston, MA; Jerry Avorn, M.D., is with the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; Eric G. Campbell, Ph.D., is with the Center for Bioethics and Humanities at the University of Colorado in Denver, CO.

Publikováno v: The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics [J Law Med Ethics] 2019 Sep; Vol. 47 (3), pp. 430-441.

Network meta-analysis comparing the effectiveness of a prescription digital therapeutic for chronic insomnia to medications and face-to-face cognitive behavioral therapy in adults.

Autor: Forma F; Pear Therapeutics (US), Inc, Boston, MA, USA., Pratiwadi R; Maple Health Group, LLC, New York, NY, USA., El-Moustaid F; Maple Health Group, LLC, New York, NY, USA., Smith N; Maple Health Group, LLC, New York, NY, USA., Thorndike F; Pear Therapeutics (US), Inc, Boston, MA, USA., Velez F; Pear Therapeutics (US), Inc, Boston, MA, USA.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2022 Oct; Vol. 38 (10), pp. 1727-1738. Date of Electronic Publication: 2022 Aug 23.